Literature DB >> 24037836

Therapeutic human monoclonal antibodies against cancer.

Jamie Jarboe1, Anumeha Gupta, M W Saif.   

Abstract

There are over 30 monoclonal antibodies that are FDA approved for a variety of diseases ranging from malignancies to autoimmune diseases to macular degeneration. These antibodies include murine, fully humanized, and chimeric antibodies. There are a number of monoclonal antibodies used in the treatment of malignancies; in fact, three of the top five grossing antibodies (bevacizumab, trastuzumab, and rituximab) are used in oncology Scolnik (mAbs 1:179-184, 2009).

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24037836     DOI： 10.1007/978-1-62703-586-6_4

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN： 1064-3745


  9 in total

1.  Clostridium difficile toxins induce VEGF-A and vascular permeability to promote disease pathogenesis.

Authors:  Jun Huang; Ciarán P Kelly; Kyriaki Bakirtzi; Javier A Villafuerte Gálvez; Dena Lyras; Steven J Mileto; Sarah Larcombe; Hua Xu; Xiaotong Yang; Kelsey S Shields; Weishu Zhu; Yi Zhang; Jeffrey D Goldsmith; Ishan J Patel; Joshua Hansen; Meijin Huang; Seppo Yla-Herttuala; Alan C Moss; Daniel Paredes-Sabja; Charalabos Pothoulakis; Yatrik M Shah; Jianping Wang; Xinhua Chen
Journal:  Nat Microbiol       Date:  2018-12-03       Impact factor: 17.745

2.  Effect of trastuzumab interchain disulfide bond cleavage on Fcγ receptor binding and antibody-dependent tumour cell phagocytosis.

Authors:  Mami Suzuki; Ayaka Yamanoi; Yusuke Machino; Michiko Ootsubo; Ken-ichi Izawa; Junya Kohroki; Yasuhiko Masuho
Journal:  J Biochem       Date:  2015-08-08       Impact factor: 3.387

3.  Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease.

Authors:  Joseph Markowitz; Taylor R Brooks; Megan C Duggan; Bonnie K Paul; Xueliang Pan; Lai Wei; Zachary Abrams; Eric Luedke; Gregory B Lesinski; Bethany Mundy-Bosse; Tanios Bekaii-Saab; William E Carson
Journal:  Cancer Immunol Immunother       Date:  2014-10-11       Impact factor: 6.968

Review 4.  Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challenges.

Authors:  Maria Vela; Mariana Aris; Mercedes Llorente; Jose A Garcia-Sanz; Leonor Kremer
Journal:  Front Immunol       Date:  2015-01-30       Impact factor: 7.561

Review 5.  Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment.

Authors:  Narendiran Rajasekaran; Cariad Chester; Atsushi Yonezawa; Xing Zhao; Holbrook E Kohrt
Journal:  Immunotargets Ther       Date:  2015-05-15

6.  Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors.

Authors:  Xiao-Yan Zhao; Babu Subramanyam; Nenad Sarapa; Sven Golfier; Harald Dinter
Journal:  Clin Cancer Drugs       Date:  2016-10

Review 7.  Adverse Events of Oncologic Immunotherapy and Their Management.

Authors:  Fedricker Diane Barber
Journal:  Asia Pac J Oncol Nurs       Date:  2019 Jul-Sep

Review 8.  Of Lymph Nodes and CLL Cells: Deciphering the Role of CCR7 in the Pathogenesis of CLL and Understanding Its Potential as Therapeutic Target.

Authors:  Carlos Cuesta-Mateos; Jennifer R Brown; Fernando Terrón; Cecilia Muñoz-Calleja
Journal:  Front Immunol       Date:  2021-03-24       Impact factor: 7.561

9.  Multi-Omics and Informatics Analysis of FFPE Tissues Derived from Melanoma Patients with Long/Short Responses to Anti-PD1 Therapy Reveals Pathways of Response.

Authors:  Saurabh K Garg; Eric A Welsh; Bin Fang; Yuliana I Hernandez; Trevor Rose; Jhanelle Gray; John M Koomen; Anders Berglund; James J Mulé; Joseph Markowitz
Journal:  Cancers (Basel)       Date:  2020-11-26       Impact factor: 6.639
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.